All stock lists
Transcode Therapeutics, Inc. (NASDAQ:RNAZ)
US · Delayed Price · Currency is USD
1.75-0.03 (-1.41%)
Insider Score
––Not scored
RNAZ Insider Score
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
RNAZ Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 23.94 K | 23.94 K | 0.00 | 4.78 K | 0.00 | 0.00 |
| Gross Profit | -23.94 K | -23.94 K | 0.00 | -4.78 K | 0.00 | 0.00 |
| SG&A Expense | 2.54 M | 2.22 B | 1.76 M | 1.40 M | 1.66 M | 951.65 K |
| R&D Expense | 3.69 M | 5.11 B | 5.48 M | 3.16 M | 2.57 M | 2.22 M |
| Operating Expenses | 6.79 M | 7.30 M | 16.03 M | 4.56 M | 4.22 M | 3.17 M |
| Operating Income | -6.79 M | -7.33 M | -16.03 M | -4.56 M | -4.22 M | -3.17 M |
| Pretax Income | -6.75 M | -17.55 M | -13.22 M | -4.86 M | -4.28 M | -12.09 M |
| Tax Provision | -300.00 | 231.31 K | 226.07 K | 0.00 | 0.00 | 0.00 |
| Net Income | -6.70 M | -17.79 M | -13.44 M | -4.86 M | -4.28 M | -12.09 M |
| EPS (Basic) | -7.17 | -21.28 | -16.42 | -5.82 | -5.13 | -70.28 |
| EPS (Diluted) | -7.17 | -21.28 | -16.42 | -5.82 | -5.13 | -70.28 |
| Shares Outstanding | 937.19 K | 916.97 K | 916.97 K | 833.68 K | 833.65 K | 172.26 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.